GlaxoSmithKline PLC (GSK) stock is expected to deviate a maximum of $0.71 from the average target price of $49.5 for the short term period. 2 Street Experts have initiated coverage on the stock with the most promising target being $50 and the most muted being $49.
GlaxoSmithKline PLC (GSK) has an average broker rating of 2, which is interpreted as a Buy, as rated by 6 equity analysts. Nonetheless, 3 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 3 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Also, Argus Research maintains its rating on GlaxoSmithKline PLC (NYSE:GSK). The global brokerage major raises the current price target from $48 per share to $50 per share. Analysts at the Argus Research have a current rating of Buy on the shares. The rating by the firm was issued on August 12, 2016.
GlaxoSmithKline PLC (NYSE:GSK): The stock opened at $43.07 on Thursday but the bulls could not build on the opening and the stock topped out at $43.19 for the day. The stock traded down to $42.88 during the day, due to lack of any buying support eventually closed down at $42.98 with a loss of -1.10% for the day. The stock had closed at $43.46 on the previous day. The total traded volume was 3,220,811 shares.
GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases. Its human immunodeficiency virus (HIV) business is managed through ViiV Healthcare. GSKs Vaccines has a portfolio of over 30 paediatric, adolescent, adult travel vaccines. GSKs Established Products Portfolio includes over 50 off-patent products, as well as its branded generics business and other local products. The Consumer Healthcare business develops and markets products in four categories, such as wellness, oral health, nutrition and skin health. Its brands include Sensodyne, Panadol, Horlicks, Polident, Paradontax, Tums, ENO, NiQuitin/Nicorette, Abreva, Zovirax and Aquafresh. It operates in the United Kingdom, the United States, Belgium and China.